Composition and method for killing of tumours
AssigneeCommonwealth Scientific and Industrial Research Organisation
InventorsGerald W. Both, Trevor J. Lockett, Peter L. Molloy, Fiona H. Cameron, Pamela J. Russell, Rosetta Martiniello-Wilks, Minoo J. Moghaddam, Ian K. Smith
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating a solid tumour in a subject, the method comprising the following steps (i) delivering to the solid tumour a composition comprising an engineered ovine atadenovirus; and (ii) administering a prodrug to the subject, wherein the engineered ovine atadenovirus comprises a promoter and a gene encoding an enzyme which converts the prodrug to a cytotoxic metabolite, the gene being under control of the promoter.
Claims5
1-29. (canceled)
A method of treating a solid tumour in a subject, the method comprising the following steps
- (i) injecting the solid tumour with a composition comprising
- (a) an engineered ovine atadenovirus comprising a probasin promoter and the prostate specific membrane enhancer sequence (PSME) operatively linked to a nucleotide sequence encoding a purine nucleoside phosphorylase (PNP) enzyme, and
- (b) a CS87 lipid having the formula
- or a CS60 lipid having the formula:
- and
- (ii) administering 6-methyl purine-2-deoxyriboside (6 MPDR) or fludarabine to the subject.
A composition comprising:
- (i) an engineered ovine atadenovirus comprising a probasin promoter and the prostate specific membrane enhancer sequence (PSME) operatively linked to a gene encoding a purine nucleoside phosphorylase (PNP) enzyme;
- and
- (ii) a CS87 lipid having the formula:
- or a CS60 lipid having the formula:
Dependencies are inferred from the claim text.